Efficacy and safety of some etiotropic therapeutic schemes for treating patients with novel coronavirus infection (COVID-19)
- Authors: Balykova L.A.1, Pavelkina V.F.1, Shmyreva N.V.1, Pyataev N.A.1, Selezneva N.M.1, Shepeleva O.I.1, Almyasheva R.Z.1
-
Affiliations:
- National Research Ogarev Mordovia State University
- Issue: Vol 8, No 3 (2020)
- Pages: 150-159
- Section: Articles
- URL: https://journals.rcsi.science/2307-9266/article/view/111637
- DOI: https://doi.org/10.19163/2307-9266-2020-8-3-150-159
- ID: 111637
Cite item
Abstract
The aim of the study is to assess the efficacy and safety of the Favipiravir (Areplivir) drug, compared to the standard etiotropic therapy in the patients hospitalized with COVID-19.
Material and methods. The research was conducted as a part of an open, randomized, multicenter comparative study of the efficacy and safety of Areplivir, 200 mg film-coated tablets (“PROMOMED RUS” LLC, Russia), in the patients hospitalized with COVID-19. The dosing regimen of Favipiravir was 1600 mg twice a day on the 1st day and 600 mg twice a day on days 2–14. Thirty nine patients were enrolled into the study with a laboratory-established diagnosis of a new type of Coronavirus infection caused by SARS-CoV-2 (confirmed) of moderate severity, with pneumonia. The group of comparison (22 patients) received standard etiotropic therapy, prescribed in accordance with the current version of the temporary guidelines for the diagnosis and treatment of COVID-19, represented mainly by Hydroxychloroquine with the dosage regimen of 800 mg on the 1st day, then 400 mg on days 2–7, and Azithromycin 500 mg once a day for 5 days. The main group (17 patients) received Favipiravir (Areplivir) as etiotropiс therapy.
Results. In the main group, the time period until fever disappeared was found to be 1.36 days shorter than in the group of comparison (p<0.05); there was a higher rate of the reduction of inflammatory changes in the lungs according to the computer tomography data (38.4% vs 14.9%, p<0.05). By the end of the treatment, there was also a lower lactate level in the blood (27.1%, p<0.05) than in the patients of the group of comparison. The evaluation of the drug efficacy ассording to the Categorical Ordinal Scale of Clinical Improvement and measurements of oxygen saturation in the blood, manifested similar positive dynamics in the patients treated ассording to various etiotropic therapy regimens. By the end of the treatment, the RNA SARS-CoV-2 tests were also negative in all the patients. As for the overall frequency of adverse events (AEs), no relevant distinctions were found between the groups. A greater part of AEs was related to hepatotoxicity, with a predominantly clinically relevant increase in alanine aminotransferase (ALT). A clinically relevant prolongation of the corrected QT interval on the standard ECG was found to occur in the standard-therapy group on day 5, while no serious AEs were registered in the main group. No serious adverse reactions were registered in patients of the main group.
Conclusion. The efficacy of the Favipiravir (Areplivir) therapy for the novel coronavirus infection has proved to be superior to the efficacy of the standard etiotropic therapy in a number of aspects. Basing on the obtained findings, Favipiravir (Areplivir) drug can be recommended for treating patients with the novel coronavirus infection of moderate severity.
Full Text
##article.viewOnOriginalSite##About the authors
Larisa A. Balykova
National Research Ogarev Mordovia State University
Author for correspondence.
Email: larisabalykova@yandex.ru
ORCID iD: 0000-0002-2290-0013
Doctor of Sciences (Medicine), Professor, the Head of the Department of pediatrics; corresponding member of the Russian Academy of Sciences; Director
Russian Federation, 26 (Bld.A), Ulyanov St., Saransk, Republic of MordoviaVera F. Pavelkina
National Research Ogarev Mordovia State University
Email: pavelkina@rambler.ru
ORCID iD: 0000-0001-9582-9986
Doctor of Sciences (Medicine), Professor, the Head of the Department of infectious diseases with courses in epidemiology, phthisiology, skin and venereal diseases
Russian Federation, 26 (Bld.A), Ulyanov St., Saransk, Republic of MordoviaNatalya V. Shmyreva
National Research Ogarev Mordovia State University
Email: shmyrevanv@yandex.ru
ORCID iD: 0000-0001-9331-7979
Candidate of Sciences (Medicine), Associate Professor of the Department of Pharmacology and Clinical Pharmacology with a course in pharmaceutical technology
Russian Federation, 26 (Bld.A), Ulyanov St., Saransk, Republic of MordoviaNikolai A. Pyataev
National Research Ogarev Mordovia State University
Email: pyataevna@mail.ru
ORCID iD: 0000-0002-9688-7640
Doctor of Sciences (Medicine), Associate Professor and the Head of the Department of Anesthesiology and Reanimatology
Russian Federation, 26 (Bld.A), Ulyanov St., Saransk, Republic of MordoviaNatalya M. Selezneva
National Research Ogarev Mordovia State University
Email: nata_rm@mail.ru
ORCID iD: 0000-0002-3004-2063
Candidate of Sciences (Medicine), Associate Professor of the Department of Hospital Therapy
Russian Federation, 26 (Bld.A), Ulyanov St., Saransk, Republic of MordoviaOlga I. Shepeleva
National Research Ogarev Mordovia State University
Email: shepeleva-oi@rambler.ru
ORCID iD: 0000-0001-8307-2787
Candidate of Sciences (Medicine), Associate Professor of the Department of Faculty therapy with courses of physiotherapy, physiotherapy exercises
Russian Federation, 26 (Bld.A), Ulyanov St., Saransk, Republic of MordoviaRimma Z. Almyasheva
National Research Ogarev Mordovia State University
Email: almiasheva.rimma@yandex.ru
ORCID iD: 0000-0001-6727-9083
Candidate of Sciences (Medicine), Associate Professor of the Department of infectious diseases with courses in epidemiology, phthisiology, skin and venereal diseases
Russian Federation, 26 (Bld.A), Ulyanov St., Saransk, Republic of MordoviaReferences
- e Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016; 14(8):523–34. doi: 10.1038/nrmicro.2016.81.
- Yang L, Tian D, Liu W. [Strategies for vaccine development of COVID-19]. Sheng Wu Gong Cheng Xue Bao. 2020; 36(4):593–604. Chinese. doi: 10.13345/j.cjb.200094.
- McCreary EK, Pogue JM. Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options. Open Forum Infect Dis. 2020 Mar 23;7(4): ofaa105. doi: 10.1093/ofid/ofaa105.
- Giovane RA, Rezai S, Cleland E, Henderson CE. Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: A review. Rev Med Virol. 2020; e2136. doi: 10.1002/rmv.2136
- Mitjà O, Clotet B. Use of antiviral drugs to reduce COVID-19 transmission. Lancet Glob Health. 2020;8(5):e639–40. doi: 10.1016/S2214-109X(20)30114-5.
- Wu R, Wang L, Kuo HD, Shannar A, Peter R, Chou PJ, Li S, Hudlikar R, Liu X, Liu Z, Poiani GJ, Amorosa L, Brunetti L, Kong AN. An Update on Current Therapeutic Drugs Treating COVID-19. Curr Pharmacol Rep. 2020; 11:1–15. doi: 10.1007/s40495-020-00216-7.
- Esposito S, Noviello S, Pagliano P. Update on treatment of COVID-19: ongoing studies between promising and disappointing results. Infez Med. 2020;28(2):198–211.
- Bhimraj A, Morgan RL, Shumaker AH, Lavergne V, Baden L, Cheng VC, Edwards KM, Gandhi R, Muller WJ, O’Horo JC, Shoham S, Murad MH, Mustafa RA, Sultan S, Falck-Ytter Y. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. Clin Infect Dis. 2020: ciaa478. doi: 10.1093/cid/ciaa478.
- Kalil AC. Treating COVID-19-Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics. JAMA. 2020;323(19):1897–1898. doi: 10.1001/jama.2020.4742.
- Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020; 395:1569-1578. doi: 10.1016/S0140-6736(20)31022-9
- Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020;382(19):1787–1799. doi: 10.1056/NEJMoa200128.
- Zhu Z, Lu Z, Xu T, Chen C, Yang G, Zha T, Lu J, Xue Y. Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19. J Infect. 2020;81(1):e21–e23. doi: 10.1016/j.jinf.2020.03.060.
- Hung IF, Lung KC, Tso EY, et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020;395(10238):1695-1704. doi: 10.1016/S0140-6736(20)31042-4
- Zhou Q, Chen V, Shannon C.P, et al. Interferon-α2b Treatment for COVID-19. Front Immunol. 2020; 11:1061. doi: 10.3389/fimmu.2020.01061
- Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care. 2020; 57:279–283. doi: 10.1016/j.jcrc.2020.03.005.
- Chen C., ZhangY., HuangJ. et al. Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial. MedRxiv. 2020:2020.03.17.20037432.
- Cai Q., Yang M., Liu D., Chen J., Shu D., Xia J., Liao X., Gu Y., Cai Q., Yang Y., Shen C., Li X., Peng L., Huang D., Zhang J., Zhang S., Wang F., Liu J., Chen L., Chen S., Wang Z., Zhang Z., Cao R., Zhong W., Liu Y., Liu L. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering (Beijing). 2020;6(10):1192-1198. doi: 10.1016/j.eng.2020.03.007
- [Vremennye metodicheskie rekomendacii MZ RF «Profilaktika, diagnostika i lechenie novoj korona-virusnoj infekcii COVID-19»]. 2020 Apr 28;6: 165
- [Vremennye metodicheskie rekomendacii MZ RF «Profilaktika, diagnostika i lechenie novoj korona-virusnoj infekcii COVID-19»]. 2020 Oct 3; 7: 166.
- WHO R&D Blueprint – COVID-19 Therapeutic Trial Synopsis Draft, February 18, 2020. Available from: https://www.who.int/blueprint/priority-diseases/key-action/COVID-19_Treatment_Trial_Design_Master_Protocol_synopsis_Final_18022020.pdf
- Inui S, Fujikawa A, Jitsu M, et al. Chest CT Findings in Cases from the Cruise Ship “Diamond Princess” with Coronavirus Disease 2019 (COVID-19). Radiol Cardiothorac Imaging. 2020;2(2):e200110. doi: 10.1148/ryct.2020200110
- [Klinicheskie rekomendacii MZ RF «Vnebol’nichnaya pnevmoniya u vzroslyh»]. 2019:97.
- Anaev EK. Blood lactate and the lungs: from theory to practice. Pulmonologiya. 2014;(6):108–114. doi: 10.18093/0869-0189-2014-0-6-108-114
- Wenzhong L; Hualan L. COVID-19: Attacks the 1-Beta Chain of Hemoglobin and Captures the Porphyrin to Inhibit Human Heme Metabolism. ChemRxiv. Preprint. https: // DOI.org/10.26434/chemrxiv.11938173.v7.
- Voennov O.V., Zagrekov V.I., Boyarinov G.A., Geras’kin V.A., Boyarinova L.V. Mechanisms of development of pulmonary injury in patients with new coronavirus infection. Medicinskij al’manah. 2020; 3 (64); 15–27.
- Chugh SS, Reinier K, Singh T, Uy-Evanado A, Socoteanu C, Peters D, Mariani R, Gunson K, Jui J. Determinants of prolonged QT interval and their contribution to sudden death risk in coronary artery disease: the Oregon Sudden Unexpected Death Study. Circulation. 2009;119(5):663–70. doi: 10.1161/CIRCULATIONAHA.108.797035.
- Simpson TF, Salazar JW, Vittinghoff E, Probert J, Iwahashi A, Olgin JE, Ursell P, Hart A, Moffatt E, Tseng ZH. Association of QT-Prolonging Medications with Risk of Autopsy-Defined Causes of Sudden Death. JAMA Intern Med. 2020;180(5):698–706. doi: 10.1001/jamainternmed.2020.0148.